Drug Trial Radar · NCT05106335
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
Last checked: Nov 20, 2026Latest source record: Aug 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Jan 6, 2022
Primary completion
May 11, 2022
Study completion May 11, 2022
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in Advanced NSCLC.
Conditions
- Advanced NSCLC
Interventions
camrelizumab + famitinibDrug
camrelizumab for intravenous injection; famitinib malate capsules for oral administration
famitinibDrug
famitinib malate capsules for oral administration
docetaxelDrug
docetaxel for intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- OSTime frame: up to 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Subei People's Hospital of Jiangsu Province
Yangzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.